Neuropathic corneal pain reduced in phase 2 trial of urcosimod

Key takeaways:

Patients who received urcosimod for 12 weeks had a change in mean pain score of 5.5 vs. 2.75 with placebo.

Okyo Pharma received $1.9 million to advance development of urcosimod.

Perspective from Hardeep Kataria, OD, FAAO

Neuropathic corneal pain was significantly reduced after 12 weeks of treatment with urcosimod in a phase 2 trial, according to a press release from Okyo Pharma .

The FDA granted urcosimod, formerly called OK-101, fast track designation in May.

Neuropathic corneal pain was significantly reduced after 12 weeks of treatment with urcosimod in a phase 2 trial. Image: Adobe Stock

Topline data of 18 patients showed that those treated with 0.05% urcosimod for 12 weeks had a change in mean pain score of 5.5 ( P = .025) while those in the placebo group h